Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anadys Pharmaceuticals, Inc.

http://www.anadyspharma.com/

Latest From Anadys Pharmaceuticals, Inc.

Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Gene Therapy Approvals

Padagis Introduces Fresh Narcan Rival In US

Padagis has added fresh competition on Narcan in the US, with its nasal naloxone spray introduced to the market as part of a trio of launches that also includes adapalene gel and betamethasone ointment.

Launches Generic Drugs

Adaptimmune Starts Planning TCR Commercialization For An Ultra Rare Patient Population

CEO Adrian Rawcliffe talked with Scrip about filing and early commercial plans for afami-cel in synovial carcinoma if it is approved by the FDA.

ImmunoOncology Cancer

Bluebird Could Find US Tailwind For Zynteglo After ICER Report

The cost-effectiveness watchdog now assumes an upfront $2.1m payment instead of five annual payments. The company switched gears to the US after the TDT gene therapy stumbled in Europe.

Gene Therapy Market Access
See All

Company Information

UsernamePublicRestriction

Register